Nautilus Biotechnology, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on October 27, 2026, disclosing financial statements and operational updates for the three and nine months ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 22, 2026, the company had 127,372,425 shares of common stock, $0.0001 par value per share, outstanding.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Platform stage: According to the filing, the Nautilus Voyager platform "remains in the development stage and subject to scientific and technical validation."
  • Principal office: The company is headquartered at 2701 Eastlake Avenue East, Seattle, Washington 98102.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Nautilus Biotechnology's Q3 2026 Filing: Platform Development and Operating Context

Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a Delaware-incorporated proteomics company, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025, including balance sheets as of September 30, 2026 and December 31, 2025, statements of operations, comprehensive loss, stockholders' equity, and cash flows, along with management's discussion and analysis.

The filing identifies the company's primary asset as the Nautilus Voyager platform, which the company disclosed "remains in the development stage and subject to scientific and technical validation." According to the filing, the company's forward-looking statements address expectations regarding the timing and progress of platform development, including a broadscale assay, plans to expand a proteoform portfolio, and a phased commercial launch plan for targeted proteoform and broadscale proteomics analysis applications. The filing cautions that these statements involve "known and unknown risks, uncertainties, and other factors" and that readers "should not place undue reliance on these forward-looking statements."

The filing also notes the company's stated concern about maintaining compliance with Nasdaq Listing Rules and the listing of its public securities on The Nasdaq Stock Market LLC, which the company listed among the subjects addressed by forward-looking statements. The registrant had Commission File Number 001-39434 and reported its IRS Employer Identification Number as 98-1541723. All financial statements included in the filing are unaudited.

What Was Disclosed

Nautilus Biotechnology filed a Form 10-Q for the quarter ended September 30, 2026, reporting 127,372,425 shares of common stock outstanding as of October 22, 2026, and describing its Nautilus Voyager platform as still in the development stage.